Oral 5‐ASA probably leads to lower adverse events compared with SASP (moderate certainty).
Oral 5‐ASA showed no clear difference in adverse events compared with comparator 5‐ASA (moderate certainty).
Oral 5‐ASA showed no clear difference in adverse events compared with placebo (high certainty).
Oral 5‐ASA showed no clear difference in serious adverse events compared with SASP (low certainty).
Oral 5‐ASA showed no clear difference in serious adverse events compared with comparator 5‐ASA (low certainty).
Oral 5‐ASA showed no clear difference in serious adverse events compared with placebo (low certainty).
Oral 5‐aminosalicylic acid showed no clear difference in adverse events compared with placebo (moderate certainty).
Oral 5‐ASA probably leads to lower withdrawal due to adverse events compared with SASP (moderate certainty).
Oral 5‐ASA showed no clear difference in withdrawal due to adverse events compared with comparator 5‐ASA (moderate certainty).
Oral 5‐ASA probably leads to lower withdrawal due to adverse events compared with placebo (moderate certainty).
The review found no eligible studies for this question.
Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with comparator 5‐aminosalicylic acid formulation (low certainty).
Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with placebo (low certainty).
It is very uncertain whether oral iron sulphate changes serious adverse events ‐ active or inactive disease (14 days) compared with oral iron hydroxide polymaltose complex (very low certainty).
It is very uncertain whether oral ferric maltol changes serious adverse events ‐ mild disease to quiescent (up to 52 weeks) compared with oral placebo (very low certainty).
It is very uncertain whether oral 5‐aminosalicylic acid changes withdrawal due to adverse events compared with comparator 5‐aminosalicylic acid formulation (very low certainty).
It is very uncertain whether oral ferric maltol changes serious adverse events (12 weeks) compared with IV ferric carboxymaltose (very low certainty).
Oral viscous budesonide showed no clear difference in withdrawals due to adverse events at 8 weeks compared with swallowed fluticasone (low certainty).
Once daily dosing showed no clear difference in adverse events compared with conventional dosing (moderate certainty).
The findings closest to your search, judged one by one by TypeSafe's Jev model.